Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Autologous, lethally irradiated melanoma cells refer to a personalized cancer vaccine created from a patient's own (autologous) melanoma tumor cells that have been rendered non-viable by lethal irradiation. These cells are often further engineered to secrete granulocyte–macrophage colony-stimulating factor (GM-CSF) via gene transfer. The purpose of this approach is to stimulate the patient’s immune system to recognize and attack residual or metastatic melanoma by presenting a broad array of tumor antigens in an immunogenic context. Upon vaccination, these modified and irradiated tumor cells attract dendritic cells and other immune effectors at the injection site, promoting antigen presentation and robust anti-tumor T-cell responses. Clinical trials have demonstrated that this strategy can induce both cellular and humoral immunity against melanoma antigens, leading to increased infiltration of immune effector cells into tumors and evidence of tumor destruction in some patients with advanced disease[1][2]. This therapy remains investigational.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on autologous, lethally irradiated melanoma cells.